Nebraska Clinical Trials Report — June 2026

For Nebraskans considering participation in clinical research, June 2026 presents a crucial window of opportunity, particularly for those looking to enroll in trials nearing their conclusion. A total of 33 clinical trials across the state are slated to close within the next 90 days, urging prompt action for interested participants. This includes 9 studies that are actively seeking healthy volunteers, offering a chance to contribute to medical science without a specific health condition.

Individuals living with certain health conditions should also act quickly to explore trials with impending deadlines. Research focusing on various cancers and vascular conditions are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Breast cancer
• Peripheral arterial disease
• Prostate cancer
• Advanced breast cancer
• AML
• AML with mutated NPM1
• Advanced solid tumor
• Amniotic band syndrome
• Asthma
• Atopic dermatitis

New Horizons: Major Trials Launching in Nebraska This Month

This June, Nebraska welcomes 15 new clinical trials, marking a significant increase from the 8 trials that opened in May 2026. This surge in new research opportunities contributes to the state's overall landscape of 719 clinical trials currently recruiting across 23 cities and 396 research sites. The new studies include several significant Phase 3 drug trials from major pharmaceutical companies, offering participants access to cutting-edge treatments for widespread health challenges like obesity and type 2 diabetes, as well as crucial vaccine development.

Among the most notable new trials:

• Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics, is sponsoring NCT07654361, a Phase 3 study titled "Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)." This substantial global study aims to enroll 3,600 participants, evaluating the long-term efficacy, safety, and tolerability of aleniglipron once daily compared with placebo for weight management.
• Another Phase 3 trial from Gasherbrum Bio, Inc. is NCT07654374, "A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)." This randomized, double-blind, placebo-controlled study targets 1,100 participants to assess the long-term efficacy, safety, and tolerability of multiple doses of aleniglipron for individuals living with overweight or obesity and Type 2 Diabetes Mellitus (T2DM).
• Pfizer is leading two important Phase 3 vaccine trials focused on pneumococcal disease. NCT07629440, "A Study to Learn About How a New Pneumococcal Vaccine Works in Infants," aims for 3,230 participants to evaluate the safety and immune response of a new vaccine against pneumonia, meningitis, and otitis media in infants. Additionally, NCT07660198, "Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adolescents," will enroll 1,200 participants to assess a new pneumococcal vaccine in older children.
• For those with type 2 diabetes, AstraZeneca is sponsoring NCT07662213, "A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus." This Phase 3 study will enroll 1,200 adults with T2DM and increased cardiovascular risk to evaluate the efficacy, safety, and tolerability of elecoglipron.
• Also from AstraZeneca, NCT07662135 is a Phase 3 study investigating "The Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin." This trial plans for 900 participants.
• Individuals with localized prostate cancer may be interested in NCT07650448, "WATER IV PCa (AS Sub-study)," sponsored by PROCEPT BioRobotics. This study aims to evaluate the safety and efficacy of Aquablation therapy in men, targeting 333 participants.

Opportunities for Healthy Volunteers and Diverse Participants

For individuals without a specific medical condition, there are significant opportunities to contribute to medical science. Of the 15 new trials launched this month, 8 are actively seeking healthy volunteers. Statewide, a total of 75 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Clinical trials in Nebraska are designed to be inclusive, with a broad range of eligibility criteria. Of the new trials, 3 include children as participants, and 10 include older adults, ensuring that research benefits diverse age groups. Additionally, 1 new trial is female-only and 1 is male-only, addressing specific health needs within these populations.

New Research Across Conditions and Interventions

The 15 new trials opening this month in Nebraska cover a diverse range of health conditions, with a strong focus on metabolic health and infectious disease prevention. The most common conditions addressed by these new studies include:

• Overweight
• Healthy
• Type 2 diabetes mellitus
• Pneumococcal disease
• Obesity
• Chronic weight management

In terms of intervention types, drug trials lead the way, accounting for 11 of the new studies. Biological and device trials each contribute 2 new studies, alongside 1 other type of research.

Geographic Spread: Omaha and Lincoln Lead the Way

Nebraska's clinical research landscape continues to be robust, with research sites spread across 23 cities. This month, the majority of new research initiatives are concentrated in the state's largest metropolitan areas. Omaha saw 9 new trials open, while Lincoln welcomed 6 new studies. However, opportunities are also expanding in other parts of the state:

• Grand Island (1 new trial)
• Kearney (1 new trial)

This distribution ensures that residents in various regions of Nebraska have access to cutting-edge research, even as Omaha and Lincoln remain central hubs for clinical investigations.

Academic institutions continue to play a vital role in the state's research ecosystem, with Creighton University and the University of Nebraska sponsoring new trials. Industry sponsors are also driving significant research efforts, with 12 new trials sponsored by pharmaceutical companies such as AstraZeneca, Gasherbrum Bio, Inc., Pfizer, and Merck Sharp & Dohme LLC.

As we move through June, the focus will remain on the ongoing enrollment in these significant Phase 3 trials and the exploration of new treatments, diagnostics, and preventive measures for a broad spectrum of health challenges across Nebraska.